Interreader Agreement and Longitudinal Progression of Incomplete/Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 03 2023
revised: 14 07 2023
accepted: 24 07 2023
medline: 4 12 2023
pubmed: 31 7 2023
entrez: 30 7 2023
Statut: ppublish

Résumé

To analyze the ability to evaluate changes over time of individual lesions of incomplete or complete retinal pigment epithelium (RPE) and outer retinal atrophy (iRORA and cRORA, respectively) in patients with intermediate age-related macular degeneration (iAMD). OCT images from patients enrolled in Proxima B clinical trial (NCT02399072) were utilized. Patients enrolled in the Proxima B clinical trial, from the cohort with geographic atrophy (GA) in 1 eye and iAMD in the other eye at baseline, were included. Junior and senior readers analyzed OCT images for the qualitative presence of 9 distinct early atrophic features (presence of zone of choroidal hypertransmission, attenuation and/or disruption of RPE, disruption of ellipsoid zone [EZ] and external limiting membrane [ELM], outer nuclear layer [ONL] thinning, outer plexiform layer [OPL]/inner nuclear layer [INL] subsidence, and hyporeflective wedge-shaped band). If deemed "present," 7 features were quantified with a predefined tolerance level of 50 μm (diameter for the zone of choroidal hypertransmission, zone of attenuation and/or disruption of the RPE, outer retinal thickness left/right vertical diameter, outer retinal thickness thinnest vertical diameter, annotation of EZ, and ELM disruption). Interreader agreements for qualitative assessments (κ-type statistics) and quantitative measurements (Bland-Altman statistics) were assessed. Progression of the lesion features over time was described. Moderate agreement was found for presence of choroidal hypertransmission (κ = 0.54), followed by ELM disruption (κ = 0.58), OPL/INL subsidence (κ = 0.46), and a hyporeflective wedge-shaped band (κ = 0.47). Quantification measurements showed that choroidal hypertransmission had the highest agreement, whereas RPE attenuation/disruption had the lowest agreement. Longitudinal adjudicated changes for quantitative measurements of lesion progression showed that choroidal hypertransmission and ELM disruption showed significant progression, whereas EZ disruption and RPE attenuation/disruption did not. The ability to evaluate changes over time for specific features of iRORA and cRORA was explored. The most robust biomarker was found to be choroidal hypertransmission, followed by ELM disruption and the qualitative markers of OPL/INL subsidence, as well as a wedge-shaped band. Disease progression over time could be assessed by some, but not all, spectral-domain OCT features that were explored. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Identifiants

pubmed: 37517799
pii: S2468-6530(23)00354-8
doi: 10.1016/j.oret.2023.07.021
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02399072']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1059-1068

Informations de copyright

Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Steffen Schmitz-Valckenberg (S)

John A. Moran Eye Center, University of Utah, Salt Lake City, Utah; GRADE Reading Center and Department of Ophthalmology, University of Bonn, Germany. Electronic address: steffen.valckenberg@hsc.utah.edu.

Marlene Saßmannshausen (M)

GRADE Reading Center and Department of Ophthalmology, University of Bonn, Germany.

Martina Braun (M)

GRADE Reading Center and Department of Ophthalmology, University of Bonn, Germany.

Verena Steffen (V)

Genentech, Inc., South San Francisco, California.

Simon S Gao (SS)

Genentech, Inc., South San Francisco, California.

Lee Honigberg (L)

Genentech, Inc., South San Francisco, California.

Daniela Ferrara (D)

Genentech, Inc., South San Francisco, California.

Maximilian Pfau (M)

GRADE Reading Center and Department of Ophthalmology, University of Bonn, Germany; Institute of Molecular and Clinical Ophthalmology, Basel, Switzerland.

Frank G Holz (FG)

GRADE Reading Center and Department of Ophthalmology, University of Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH